Adsorption column for myasthenia gravis treatment: Medisorba MG-50

Ther Apher Dial. 2003 Feb;7(1):78-84. doi: 10.1046/j.1526-0968.2003.00008.x.

Abstract

Adsorption column Medisorba MG-50 (Kuraray Medical Inc.) for the treatment of myasthenia gravis (MG) is introduced. The adsorbent in this column is composed of cellulose beads as carrier material and covalent-bound synthetic peptide as a ligand that has a specific affinity to the pathogenic anti-acetylcholine receptor antibody of MG. The amino acid sequence of the peptide is modified from the segment of alpha 183-200 of the torpedo acetylcholine receptor (AChR) protein, and the segment is the acetylcholine binding site on AChR and the target site of anti-AChR antibody. The adsorbent showed specific adsorption characteristics to the anti-ACHR antibody (blocking antibody) in vitro. Clinically, MG-50 is used in plasma-perfusion therapy, and it is recognized that MG-50 specifically reduces blocking antibody titer and improves MG symptoms. MG-50 is approved in Japan.

Publication types

  • Review

MeSH terms

  • Autoantibodies / blood*
  • Autoantibodies / immunology*
  • Clinical Trials as Topic
  • Humans
  • Immunosorbent Techniques / instrumentation*
  • Immunosorbents / immunology
  • Myasthenia Gravis / immunology
  • Myasthenia Gravis / therapy*
  • Peptide Fragments / immunology
  • Receptors, Cholinergic / immunology*
  • Sensitivity and Specificity

Substances

  • Autoantibodies
  • Immunosorbents
  • Peptide Fragments
  • Receptors, Cholinergic